This finding warrants further investigation to explore the potential of MrgD as a predictive biomarker for treatment selection, offering a renewed role for therapies currently relegated to third-line use in advanced ccRCC protocols [5,6]. The gene discussed is MRGPRD; the disease is nonpapillary renal cell carcinoma.